• Massoud Vosough, Shirin Moossavi, Soura Mardpour, Shahram Akhlaghpoor, Vajiheh Azimian, Neda Jarughi, Seyedeh-Esmat Hosseini, Mandana Ashrafi, Sepideh Nikfam, Nasser Aghdami, Reza Malekzadeh, Mehdi Mohamadnejad, and Hossein Baharvand.
• Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
• Arch Iran Med. 2016 Feb 1; 19 (2): 131-6.

BackgroundTransplantation of mesenchymal stem cells (MSCs) in combination with pioglitazone, an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), can reduce liver fibrosis in models of liver injury. In this study, we conducted a pilot study of intraportal infusion of autologous MSCs in combination with pioglitazone to assess safety, feasibility, and effectiveness in patients with compensated cirrhosis.MethodsTwo patients with compensated cirrhosis were enrolled in this study. Intraportal autologous bone marrow-derived MSCs were transplanted twice (6 months interval) to the patients. Meanwhile, 30 mg/day pioglitazone was prescribed for 12 months.  Patients were assessed at baseline and months 1, 3, 6, and 12 post-infusion.ResultsProcedural complications or any major adverse effects did not occur in this pilot study.  The patients' clinical conditions remained stable with no evidence of deterioration during the course of the study. A transient improvement in the Model for End-Stage Liver Disease (MELD) score was observed at month 3 post-infusion in one patient, which eventually returned to baseline at month 12.ConclusionThe combination of pioglitazone with MSCs is safe and feasible. The data justify further study of the combination therapy in cirrhotic patients.

21 keywords...

hide…